Sugi Predict

Sugi Predict / Compounds / SCHEMBL15095486

SCHEMBL15095486

SCHEMBL15095486

CC(=O)OCCCN1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ PAOX Q6QHF9 1/20 0.49
▸ HRH3 Q9Y5N1 4/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CHRM2 P08172 1/20 0.49
▸ CHRM1 P11229 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ SCN1A P35498 1/20 0.49
▸ HTR2B P41595 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ SCN2A Q99250 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.49
▸ SCN3A Q9NY46 1/20 0.49
▸ LMNA P02545 2/20 0.47
▸ USP2 O75604 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17696813 0.95 KDM4E (0.49) GAAKDM4EPKMPAOXALDH1A1
SCHEMBL65772 0.89 ATM (0.54) GAAKDM4EALDH1A1LMNATDP1
SCHEMBL16845053 0.84 KDM4E (0.54) GAAKDM4EPKMHRH3MAPK1
SCHEMBL608308 0.83 GAA (0.48) GAAKDM4EPKMPAOXHRH3
SCHEMBL21861967 0.83 CYP2D6 (0.51) GAAKDM4EHRH3MAPK1ALDH1A1
SCHEMBL16845057 0.83 TDP1 (0.51) GAAKDM4EPKMPAOXHRH3
SCHEMBL13265466 0.83 HRH3 (0.54) GAAKDM4EPKMHRH3MAPK1
SCHEMBL19204364 0.83 KDM4E (0.50) GAAKDM4EPKMPAOXHRH3
Hydrochloric Acid SCHEMBL21854850 0.82 KDM4E (0.47) GAAKDM4EPKMPAOXHRH3
SCHEMBL8939921 0.82 GAA (0.53) GAAKDM4EPKMHRH3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220135763-A1 BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING BIO-ELECTRODE, AND REACTION COMPOSITE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-05-05 — — US disclosed
US-9845332-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-19 — — US disclosed
US-20170320895-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-11-09 — — US disclosed
US-9724359-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-08 — — US disclosed
US-9725448-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-08 — — US disclosed
US-20170217959-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-03 — — US disclosed
US-9688692-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-06-27 — — US disclosed
US-20170066764-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-03-09 — — US disclosed
US-9555041-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-01-31 — — US disclosed
US-20170022219-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-01-26 — — US disclosed
US-20140364603-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-12-11 — — US disclosed
US-20140315790-A1 AMINOTHIAZOLES AND THEIR USES BUSHELL SIMON (US) 2014-10-23 — — US disclosed
US-8853427-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-10-07 — — US disclosed
US-8846913-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-09-30 — — US disclosed
US-20140046053-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-02-13 — — US disclosed
US-20140011997-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-01-09 — — US disclosed
US-8563512-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-10-22 — — US disclosed
EP-2044101-B1 AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS NOVARTIS AG (CH) 2013-10-09 — — EP disclosed
US-20130245260-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2013-09-19 — — US disclosed
US-8481044-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011997-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 125/4885KDM4E 2334/4885PKM 3693/4885
US-20170022219-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 125/4885KDM4E 2334/4885PKM 3693/4885
US-20170320895-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 125/4885KDM4E 2334/4885PKM 3693/4885
US-20140046053-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 125/4885KDM4E 2334/4885PKM 3693/4885
US-20140315790-A1 AMINOTHIAZOLES AND THEIR USES ABAT, AADAT, GOT2 GAA 459/4885KDM4E 3853/4885PKM 1097/4885
US-20170217959-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 125/4885KDM4E 2334/4885PKM 3693/4885
US-20170066764-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB GAA 176/4885KDM4E 2255/4885PKM 3337/4885
US-20140364603-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GAA 126/4885KDM4E 1928/4885PKM 3692/4885
US-20130245260-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB GAA 176/4885KDM4E 2255/4885PKM 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.